Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) announced Thursday that it had treated the last patient in the Phase 2b portion of its multinational Phase 2b/3 study of Ifenprodil (NP-120), a potential COVID-19 treatment.
In a statement, the company said the patient had completed treatment as well as the required two-week follow up.
Vancouver-based Algernon recently announced positive trending interim data from the Phase 2b portion of the study. Full results are expected before the end of February.
READ: Algernon provides additional facts on its interim data for its Phase 2b/3 Ifenprodil COVID-19 study
CEO Christopher Moreau called the news “another important step” for the company.
“Now that we have announced final patient out of the Ifenprodil COVID-19 study, we can begin preparations for the final data report,” Moreau told shareholders.
Ifenprodil is an N-methyl-D-aspartate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can cause the dangerous “cytokine storm” that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.
The firm cautioned it is not making any express or implied claim that Ifenprodil is effective against COVID-19 at this time.
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas